TARA: TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities

TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This financing will be used to scale TARA's cardiac tissue engineering platform technology and advance its drug discovery programs.